Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance. The quarter saw substantial revenue growth, encouraging confidence in Gilead ...
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% ...
The company expects FDA approval this summer of its twice-a-year injectable HIV prevention drug lenacapavir. Gilead Sciences Inc.'s sales exceeded Wall Street expectations last year — thanks in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback